{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:18:47Z","timestamp":1791919127513,"version":"4.3.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zhongshan City Social Public Welfare Technology Research Project","award":["2022B1153"],"award-info":[{"award-number":["2022B1153"]}]},{"name":"a grant from Traditional Chinese Medicine Project of Zhongshan Science","award":["2024B3029"],"award-info":[{"award-number":["2024B3029"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:p>\n                    This study investigates the expression level of cathepsin D (CTSD) in the serum of patients with acute myeloid leukemia (AML) and its clinical significance and evaluates its potential value as a prognostic biomarker for AML. Bioinformatics analysis was performed to examine the expression profile and prognostic correlation of CTSD in AML. A total of 63 newly diagnosed AML patients and 50 healthy controls were enrolled in validation. Serum CTSD levels were measured using enzyme-linked immunosorbent assay, and their associations with clinical characteristics, treatment response, and prognosis were analyzed. Bioinformatics analysis showed CTSD may be a potential factor for poor prognosis in AML patients. Validation through sample analysis confirmed that the serum CTSD level in AML patients (400.00\u2005\u00b1\u2005240.00\u2005pg\/mL) was significantly higher than in healthy controls(\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). CTSD expression was positively correlated with peripheral white blood cell count and bone marrow blast percentage. Patients who achieved complete remission after chemotherapy had significantly lower CTSD levels than those in the non-remission and partial remission groups. Survival analysis revealed that patients with high CTSD expression had significantly shorter disease-free survival (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.021) and overall survival (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.026). Risk stratification showed the level of CTSD was lower in favorable group than that in intermediate and poor groups. Multivariate regression analysis showed that CTSD was a significant independent risk factor in both the overall survival and disease-free survival models, with a hazard ratio 1.002. The expression level of CTSD in peripheral serum is significantly elevated in AML patients and is closely associated with disease progression and poor prognosis. CTSD may serve as a potential biomarker for AML prognostic assessment.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045313","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:04:21Z","timestamp":1762211061000},"page":"e45313","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Expression and prognostic significance of cathepsin D in acute myeloid leukemia"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2724-9992","authenticated-orcid":false,"given":"Hui","family":"Han","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Zhongshan City People\u2019s Hospital, Zhongshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Zhongshan City People\u2019s Hospital, Zhongshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinye","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Zhongshan City People\u2019s Hospital, Zhongshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Zhongshan City People\u2019s Hospital, Zhongshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8097-9244","authenticated-orcid":false,"given":"Weijia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Zhongshan City People\u2019s Hospital, Zhongshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges.","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"key":"R2-20260915","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: new drugs and new challenges.","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"103281","DOI":"10.1016\/j.critrevonc.2021.103281","article-title":"Update on drug transporter proteins in acute myeloid leukemia: pathological implication and clinical setting.","volume":"160","author":"Vasconcelos","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s12033-010-9321-2","article-title":"Multiple drug resistance mechanisms in cancer.","volume":"46","author":"Baguley","year":"2010","journal-title":"Mol Biotechnol"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.canlet.2005.06.007","article-title":"Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis.","volume":"237","author":"Liaudet-Coopman","year":"2006","journal-title":"Cancer Lett"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cts.12920","article-title":"Identification of BAG2 and cathepsin D as plasma biomarkers for Parkinson\u2019s disease.","volume":"14","author":"Kang","year":"2021","journal-title":"Clin Transl Sci"},{"key":"R7-20260915","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1080\/15548627.2020.1761219","article-title":"Restoration of CTSD (cathepsin D) and lysosomal function in stroke is neuroprotective.","volume":"17","author":"Hossain","year":"2021","journal-title":"Autophagy"},{"key":"R8-20260915","doi-asserted-by":"crossref","first-page":"1758835920927838","DOI":"10.1177\/1758835920927838","article-title":"Prognostic role of high cathepsin D expression in breast cancer: a systematic review and meta-analysis.","volume":"12","author":"Kang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"R9-20260915","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms.","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data.","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 ELN recommendations from an International Expert Panel.","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions.","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41419-025-07949-7","article-title":"Cathepsin D promotes acute myeloid leukemia progression through stabilization of the anti-apoptotic proteins.","volume":"16","author":"Jiang","year":"2025","journal-title":"Cell Death Dis"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10549-024-07293-y","article-title":"Expression of cathepsin D in early-stage breast cancer and its prognostic and predictive value.","volume":"206","author":"Alhudiri","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.31557\/APJCP.2022.23.6.2017","article-title":"Targeted proteins reveal cathepsin D as a novel biomarker in differentiating hepatocellular carcinoma from cirrhosis and other liver cancers.","volume":"23","author":"Chuaypen","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1080\/15548627.2020.1752497","article-title":"Autophagy triggers CTSD (cathepsin D) maturation and localization inside cells to promote apoptosis.","volume":"17","author":"Di","year":"2021","journal-title":"Autophagy"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"6988","DOI":"10.21037\/tcr-19-2133","article-title":"MiR-185-3p regulates epithelial mesenchymal transition via PI3K\/Akt signaling pathway by targeting cathepsin D in gastric cancer cells.","volume":"9","author":"Huang","year":"2020","journal-title":"Transl Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:02:22Z","timestamp":1789498942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":17,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045313","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"2025-07-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}